Pain Management
Please note that you will be redirected to our sister website, EmergingSolutionsinPain.com (ESP) - Continuing Education Center, where these courses are maintained, unless otherwise noted. You will need to log in if you are already a member of the ESP website or take a minute to register for complimentary membership.

| Electronic Prescription Monitoring Programs: A Data-Reporting Tool Designed to Prevent Drug Diversion David B. Brushwood, RPh, JD | |
Release Date: October 01, 2007 Expiration Date: October 01, 2010 |
| Professor Brushwood provides a clear and concise update on electronic prescription monitoring and provides case studies that highlight the relevancy of its use in patient management. |
 |
| |

| When Should Opioids Be Discontinued? Assessing Aberrant Medication-Use Behaviors in Patients with Chronic Pain Penelope P. Ziegler, MD, FASAM | |
Release Date: April 01, 2008 Expiration Date: April 01, 2011 |
| Dr. Ziegler highlights some of the behaviors that the practitioner may encounter in a pain management practice and describes how they may be effectively managed. |
 |
| |

| A Multidisciplinary Approach to the Medical Management of Sleep, Chronic Pain, and Driving Bradley J. Schnierow, MD, MS and Joseph Shurman, MD | |
Release Date: May 07, 2008 Expiration Date: May 07, 2011 |
| Drs. Schnierow and Shurman discuss chronic pain and comorbid diseases and syndromes which often induce or exacerbate sleep disorders; and in turn, sleep disorders which may exacerbate chronic pain. |
 |
| |

| Appropriate Candidates for Opioid Therapy Lynn R. Webster, MD | |
Release Date: September 02, 2008 Expiration Date: September 02, 2011 |
| Dr. Webster discusses the importance of assessing a patient's suitability for opioid therapy to maximize treatment outcomes. |
 |
| |

| Evidence-Based Guidelines for Opioid Therapy Tabitha A. Washington, MD, MS and Gilbert J. Fanciullo, MD, MS | |
Release Date: November 14, 2008 Expiration Date: November 14, 2011 |
| Drs. Washington and Fanciullo discuss the development of CPGs, along with the strengths and weaknesses of CPGs for opioid therapy. |
 |
| |